AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-19. (cancelled)

20.(new) An isolated peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 3, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).

21.(new) The isolated peptide of claim 20, wherein the amino sequence of said peptide differs from SEQ ID NO: 2 or SEQ ID NO: 3 by a conservative substitution of at least one amino acid.

22. (new) The isolated peptide of claim 20, wherein the amino acid sequence of said peptide consists of SEQ ID NO: 2 or SEQ ID NO: 3.

23. (new) An isolated nucleic acid comprising a sequence that encodes the isolated peptide of claim 20.

24. (new) The isolated nucleic acid of claim 23, wherein the sequence of said nucleic acid comprises the nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

25. (new) A method of producing the isolated peptide of claim 20, said method comprising synthesizing said peptide by chemical means.

26. (new) A method of producing the isolated peptide of claim 20, said method comprising culturing a host cell transformed with a vector containing a nucleic acid that encodes said isolated peptide, under conditions permitting the expression of the peptide.

27. (new) A pharmaceutical composition comprising the isolated peptide of claim 20, and at least one pharmaceutically acceptable excipient.

28. (new) The pharmaceutical composition of claim 27, further comprising a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

29. (new) The pharmaceutical composition of claim 28, wherein the amino acid sequence of said further peptide consists of SEQ ID NO: 4.

30. (new) The pharmaceutical composition of claim 28, comprising:

(a) the peptide consisting of the amino acid sequence of SEQ ID NO: 2;

(b) the peptide consisting of the amino acid sequence of SEQ ID NO: 3; and

(c) the peptide consisting of the amino acid sequence of SEQ ID NO: 4.

31. (new) A pharmaceutical composition comprising a nucleic acid that comprises a sequence that encodes the isolated peptide of claim 20, and at least one pharmaceutically acceptable excipient.

32. (new) The pharmaceutical composition of claim 31, further comprising a nucleic acid that comprises a sequence that encodes a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

33. (new) The pharmaceutical composition of claim 32, comprising:

(a) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 2 ;

(b) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 3 ; and

(c) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 4.

34. (new) The pharmaceutical composition of claim 32, wherein said nucleic acids (a) to (c) are carried in a single vector.

35. (new) A method for preparing a medicament for the treatment of a pathology associated with an angiogenesis, comprising adding the isolated peptide of claim 20 to a pharmaceutically acceptable vehicle.

36. (new) The method of claim 35, wherein said isolated peptide is combined with a second peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

37. (new) The method of claim 35, wherein the amino sequence of said second peptide consists of SEQ ID NO: 4.

38. (new) A method for preparing a medicament for the treatment of a pathology associated with an angiogenesis, comprising adding the nucleic acid of claim 23 to a pharmaceutically acceptable vehicle.

39. (new) The method of claim 38, wherein the nucleic acid comprises a sequence that encodes a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

40. (new) The method of claim 35, wherein the pathology is a tumour, an ocular lesion, rheumatoid polyarthritis or a skin disease.